AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Saturday, March 28, 2020	
07:30-08:30	**E-Poster Presentations (Exhibition Area)**
08:30-10:10	**ALS AND ALS-PDC**
Chairs:	**Altin Kuqo**, Albania |
08:30-09:20	**ALS should not be considered a neuromuscular disorder.** *Capsule: ALS is now recognized to have clinical, histopathological and genetic overlap with FTD. Brain-based pathology is consistently identifiable, yet ALS frequently continues to be classified alongside neuromuscular disorders of peripheral nerves, rather than cerebral neurodegenerative disorders, which may have a detrimental impact on research funding and restrict optimal collaboration.*
08:30-08:40	Host: **Giancarlo Logroscino**, Italy
08:40-08:55	Yes: **Michael van Es**, The Netherlands
08:55-09:10	No: **Monica Povedano Panades**, Spain
09:10-09:20	Discussion and rebuttals
09:20-10:10	**Do we know the cause of ALS-PDC?** *Capsule: Pacific ALS-PDC may illuminate understanding of the causes of ALS, atypical parkinsonism and related disorders. ALS-PDC is a familial and sporadic neurodegenerative disease featured neuropathologically by a tau-dominated polyproteinopathy. Is ALS-PDC primarily a genetic disease? Others propose that environmental factors dominate the etiology of ALS-PDC.*
09:20-09:30	Host: **Albert Ludolph**, Germany
09:30-09:45	Yes: **Peter Spencer**, USA
09:45-10:00	No: **Helmar Lehmann**, Germany
10:00-10:10	Discussion and rebuttals
10:10-10:25	***Coffee Break***
10:25-12:05	**ALS THERAPY**
Chairs:	
10:25-11:15	**Patients should set the agenda for therapeutic trials in ALS.** *Capsule: Research being carried out 'with' or 'by' members of the public rather than 'to', 'about' or 'for' them, underpins an increasing drive of many grant-awarding bodies for applicants to demonstrate public and patient involvement (PPI). ALS patients are understandably desperate for more effective therapy and frequently want to "try anything". Placebo-controlled trials may be problematic in rapidly-progressive diseases. 'Right-to-try' legislation challenges the traditional model of physician-as-expert, while unfiltered information disseminated through social media by 'expert patients' and self-appointed advocacy groups may adversely distort the research agenda.*
10:25-10:35	Host: **Albert Ludolph**, Germany
10:35-10:50	Yes: **Paul Wicks**, USA
10:50-11:05	No:
11:05-11:15	Discussion and rebuttals
11:15-12:05	**The study of mice has been detrimental to developing therapy for ALS.** *Capsule: ALS is a highly-selective neurodegeneration involving motor and extra-motor neuronal networks possibly unique to humans. Twenty-five years since the development of the SOD1 mouse model of ALS, there are currently only two modestly disease-modifying therapies for the human disorder. Have these models helped or slowed the development of therapies?*
11:15-11:25	Host:
11:25-11:40	Yes: **Peter Bede**, Ireland
11:40-11:55	No: **Elizabeth Fisher**, UK
11:55-12:05	Discussion and rebuttals
12:05-12:15	***Short Break***
12:15-13:15	**Industry Symposium**
13:15-14:15	***Lunch Break***
13:15-14:15	**Meet the Expert**